Success of Direct-Acting, Antiviral-Based Therapy for Chronic Hepatitis C Is Not Affected by Type 2 Diabetes | Zendy

Blake Niccum | Zendy; Jonathan G. Stine | Zendy; Javelle A. Wynter | Zendy; Virginia Kelly | Zendy; Stephen H. Caldwell | Zendy; Neeral L. Shah | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Success of Direct-Acting, Antiviral-Based Therapy for Chronic Hepatitis C Is Not Affected by Type 2 Diabetes

Author(s) -

Blake Niccum,

Jonathan G. Stine,

Javelle A. Wynter,

Virginia Kelly,

Stephen H. Caldwell,

Neeral L. Shah

Publication year - 2019

Publication title -

clinical diabetes

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.931

H-Index - 37

eISSN - 1945-4953

pISSN - 0891-8929

DOI - 10.2337/cd18-0112

Subject(s) - medicine , type 2 diabetes , hepatitis c virus , diabetes mellitus , chronic hepatitis , hepatitis c , interferon , antiviral therapy , combination therapy , immunology , virus , endocrinology

Chronic hepatitis C virus (HCV) is a risk factor for type 2 diabetes. In the era of interferon-based HCV therapy, type 2 diabetes was associated with decreased likelihood of sustained virologic response (SVR). Preliminary studies suggest that type 2 diabetes may not reduce the efficacy of regimens involving direct-acting antiviral (DAA) medications. We aimed to determine whether preexisting type 2 diabetes is associated with a reduced rate of SVR achieved 12 weeks after treatment of HCV with DAA-based regimens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research